Section Arrow
ARGX.NASDAQ
- argenx SE
Quotes are at least 15-min delayed:2026/07/15 17:23 EDT
After Hours
Last
 862.93
0 (0.00%)
Bid
849.9
Ask
869.7
High 862.93 
Low 849.9 
Volume 3.41K 
Regular Hours (Closed)
Last
 862.93
+3.5 (+0.41%)
Day High 
866.72 
Prev. Close
859.43 
1-M High
953.58 
Volume 
177.22K 
Bid
849.9
Ask
869.7
Day Low
854.17 
Open
860.67 
1-M Low
837.74 
Market Cap 
53.45B 
Currency 美元 
P/E 38.18 
%Yield -- 
10-SMA 905.18 
20-SMA 894.12 
50-SMA 852.19 
52-W High 953.58 
52-W Low 560.9075 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
22.51/29.48
Enterprise Value
53.48B
Balance Sheet
Book Value Per Share
117.76
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
4.15B
Operating Revenue Per Share
15.98
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VIVSVivoSim Lab Inc0.8529+0.0181+2.17%0.47PE
After Hours 0.835 -0.0179 -2.10%
LIMNLiminatus Pharma Inc0.1145+0.011+10.63%-- 
After Hours 0.12 +0.0055 +4.80%
IOVAIovance Biotherapeutics4.74+0.81+20.61%-- 
After Hours 4.7001 -0.0399 -0.84%
ERNAErnexa Therapeutics Inc.6.73+0.67+11.06%0.01PE
After Hours 7.2 +0.47 +6.98%
PHIOPhio Pharmaceuticals Corp0.8901-0.1399-13.58%-- 
After Hours 0.9473 +0.0572 +6.43%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.